Other News To Note
Tuesday, March 15, 2011
Cellceutix Corp., of Beverly, Mass., reported that Formatech Inc., of Andover, Mass., has begun production of Kevetrin for clinical trials. Cellceutix is finalizing an investigational new drug application, which it hopes to submit in May to the FDA, for Kevetrin for the treatment of drug-resistant cancers. If approved, the drug compound would be the first in its class to be used as an anticancer agent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.